Skip to content
★ Sign in to follow
BM

Bryan M. Reasons

Directeur
Societal CDMO, Inc.Aclaris Therapeutics, Inc.Mallinckrodt plcAmneal Pharmaceuticals, Inc.Impax Laboratories, LLC
Total declarations
55
Companies
5
▲ Purchases (2 ops.)
€66k
▼ Sales (2 ops.)
€240k

Latest filing published 02 Jan 2025 for Mallinckrodt plc.

Filing timeline

BuySale
Bryan M. Reasons

Insider track record

Disclosed buys
2
Disclosed sells
2
Signal history

Closed purchases

Market purchases
2

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Bryan M. Reasons: trading record in brief

Bryan M. Reasons (senior executive) discloses dealings in 5 companies, chiefly Impax Laboratories, LLC, Societal CDMO, Inc. and Mallinckrodt plc. The record holds 55 filings, for trades running from 26 October 2012 to 1 January 2025.

The open-market side counts 2 purchases for €66k alongside 2 sales for €240k. Taken together, the sales exceed the purchases by €174k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 38 share grants and 7 option exercises.

The newest entry dates from 2 January 2025: a share grant, in Mallinckrodt plc. The most recent open-market purchase was published on 28 August 2023, 1,168 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Bryan M. Reasons

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations55 total

25 of 55 declarations